Sight Sciences (SGHT) Q2 2026: Interventional Dry Eye Revenue Triples, Expanding Recurring Platform
Sight Sciences delivered a breakout quarter, with interventional dry eye revenue nearly tripling and both core segments accelerating. The company’s dual-platform model—anchored by minimally invasive procedures for glaucoma and dry eye—demonstrated operating leverage, robust account expansion, and early signs of durable recurring revenue. Raised guidance and improving cost discipline signal a maturing, cash flow-oriented business model as payer access and new product launches extend the growth runway.
Summary
- Recurring Revenue Model Gains Traction: Interventional dry eye adoption accelerated, supporting a shift toward higher-margin, repeatable sales.
- Operating Discipline Unlocks Margin Expansion: Cost controls and efficiency gains drive rapid progress toward cash flow breakeven.
- Payer Access and Product Pipeline Extend Growth: Expanded reimbursement and new glaucoma technology set up multi-year opportunity.
Business Overview
Sight Sciences develops and commercializes procedure-based devices targeting glaucoma and dry eye—two of the most prevalent anterior eye diseases. The company’s revenue comes from two main segments: interventional glaucoma (Omni and Scion, implant-free devices for minimally invasive glaucoma surgery) and interventional dry eye (TierCare, a reimbursed in-office solution for meibomian gland dysfunction). Both businesses leverage recurring device and consumable sales to build durable customer relationships within ophthalmology and optometry practices.
Performance Analysis
Sight Sciences posted its strongest revenue growth in three years, propelled by a 20% year-over-year increase and robust contributions from both interventional segments. Interventional dry eye revenue reached $2.7 million, nearly tripling sequentially as TierCare adoption scaled in the reimbursed market. Active dry eye accounts nearly doubled, and average utilization per account also increased, signaling both breadth and depth of adoption. Interventional glaucoma, the company’s legacy business and largest segment, delivered its highest growth rate since late 2024, with broad-based momentum across accounts, procedure volumes, and pricing.
Gross margin expanded to 91%, aided by a one-time tariff refund, but underlying margin strength was also evident in both segments. Operating expenses fell 11% year-over-year, reflecting the impact of a prior workforce reduction and ongoing cost discipline. Net loss narrowed sharply, and normalized cash burn dropped 81% from the prior year, underscoring the company’s progress toward self-sustaining operations.
- Dry Eye Business Surges: Record account growth and utilization drove a step-change in recurring revenue, with two-thirds of smart lid sales tied to existing glaucoma customers.
- Glaucoma Platform Reaccelerates: Active accounts hit an all-time high, and utilization rebounded to pre-LCD disruption levels.
- Expense Controls Drive Leverage: Lower personnel costs, streamlined operations, and improved efficiency delivered margin gains and sharply reduced cash usage.
Guidance was raised for both revenue and adjusted operating expenses, reflecting management’s confidence in sustained segment momentum and cost control.
Executive Commentary
"We delivered a strong second quarter, with revenue growing 20% year over year... This performance reflected growth in both segments with interventional dry eye achieving record revenue as TierCare adoption scaled in the reimbursed market and interventional glaucoma delivering its highest year over year growth rate since the fourth quarter of 2024."
Paul Badawi, Co-founder & Chief Executive Officer
"Adjusted operating expenses were $22.3 million, down 8% compared to $24.4 million in the same period in the prior year... This reflects meaningful improvement and underscores the progress we are making toward cash flow breakeven."
Jim Rodberg, Chief Financial Officer
Strategic Positioning
1. Dual-Platform Synergy: Intersection of Intervention
Sight Sciences leverages overlapping patient populations and procedural workflows in glaucoma and dry eye to deepen customer engagement and accelerate cross-segment adoption. Two-thirds of TierCare volume came from existing glaucoma accounts, demonstrating the power of established relationships to drive new product uptake and recurring revenue.
2. Reimbursed Dry Eye Market Creation
The company is pioneering the reimbursed procedural dry eye category, with TierCare positioned as the only minimally invasive, payer-backed intervention supported by robust clinical data. Recent payer wins expanded covered lives by 4.1 million, and management sees further market access gains as a key growth lever through 2027.
3. Glaucoma Franchise Strength and Expansion
Omni and Scion continue to gain traction as implant-free solutions in both combo cataract and standalone procedures. All major national payers now provide coverage, and the upcoming OmniUltra launch—featuring single-pass canaloplasty and TruSync Plus automation—aims to further differentiate the portfolio and deepen surgeon loyalty.
4. Operational Discipline and Cash Flow Focus
Sight Sciences has transitioned from a high-growth, high-burn model to one emphasizing operating leverage and capital efficiency. Management expects to reach cash flow breakeven without new equity, balancing targeted commercial investments with expense discipline.
5. Pipeline and Market Development
With OmniUltra set for a staged launch beginning in Q4 and continued investments in market access for TierCare, the company is positioned to sustain innovation-driven growth. Early feedback from surgeons and payers will be critical in scaling new products and expanding addressable markets.
Key Considerations
This quarter marked a strategic inflection for Sight Sciences as it transitions toward a more mature, recurring revenue model with improving operating leverage. Investors should weigh both the near-term execution and the long-term implications of payer access, competitive dynamics, and portfolio innovation.
Key Considerations:
- Recurring Revenue Platform Expands: TierCare’s rapid adoption and integration into existing glaucoma accounts support a higher proportion of repeatable, high-margin sales.
- Payer Access Is a Key Growth Lever: Additional fee schedules and coverage policies could accelerate dry eye adoption beyond current guidance.
- Operational Efficiency Is Sustainable: Cost discipline has become embedded, but management plans selective reinvestment to support market development and pipeline launches.
- Glaucoma Market Stability Returns: LCD disruption has subsided, and both combo cataract and standalone segments are contributing to growth.
- Litigation Windfall Remains Uncertain: Alcon patent litigation could provide a material cash inflow, but timing and outcome remain subject to appeal.
Risks
Continued reimbursement expansion is critical—delays or reversals in payer coverage could slow dry eye adoption and revenue ramp. Market development for standalone glaucoma procedures remains early, and competitive responses from cash-pay alternatives or new entrants could pressure pricing and market share. Litigation outcomes, while potentially positive, are not guaranteed and introduce additional uncertainty.
Forward Outlook
For Q3 2026, Sight Sciences guided to:
- Total revenue growth in the mid to high teens year-over-year
- Interventional glaucoma growth in the mid-single digits, with typical Q3 seasonality
- Interventional dry eye revenue of approximately $3 million, continuing sequential growth
For full-year 2026, management raised guidance to:
- Total revenue of $88 to $92 million (14 to 19% growth)
- Adjusted operating expenses of $92 to $94 million (5 to 7% increase)
Management emphasized that no incremental payer wins are assumed in the dry eye guidance, providing potential upside if additional coverage is secured. Selective investments in commercial infrastructure and market access will continue, but cost discipline remains a priority.
Takeaways
- Recurring Platform Momentum: TierCare’s rapid scaling validates the reimbursed dry eye model and deepens the recurring revenue base, with crossover from glaucoma customers providing a durable advantage.
- Operating Leverage Is Real: Expense discipline and margin gains are translating into sharply reduced cash burn, with breakeven in sight even as targeted investments continue.
- Upside Hinges on Payer Access and Pipeline Execution: Additional dry eye coverage and the successful OmniUltra launch could drive further outperformance, while operational stability positions the company to capitalize on sector tailwinds.
Conclusion
Sight Sciences’ Q2 marks a turning point, with both core franchises accelerating and the recurring revenue model taking hold. The company’s disciplined execution, payer expansion, and pipeline progress set the stage for sustained growth and cash flow improvement, though continued vigilance on market access and competitive response is warranted.
Industry Read-Through
Sight Sciences’ results highlight a sector-wide shift toward reimbursed, minimally invasive procedural care in ophthalmology. The rapid scaling of TierCare underscores provider demand for payer-backed, office-based interventions, while the rebound in glaucoma procedure volume signals stabilization post-reimbursement disruption. Competitors in both glaucoma and dry eye should expect increased pressure to deliver robust clinical and economic data to win payer support. Recurring device and consumable models are gaining favor as practices seek workflow-compatible, reimbursed solutions—a trend likely to reshape medtech commercial strategies across eye care and other procedure-driven specialties.